L’entreprise basée à Paris propose une plateforme de télésurveillance du diabète qui améliore la collaboration patient-praticien
Palo Alto, Californie (États-Unis) et Paris (France), le 16 mars 2022 – Glooko Inc., l’un des principaux fournisseurs de solutions de télésurveillance de patients et de gestion des données pour le diabète et les autres maladies chroniques, annonce aujourd’hui l’acquisition de DIABNEXT. Installée à Paris, cette entreprise propose une plateforme de télémédecine qui aide les patients diabétiques à mieux gérer leur maladie et à rester en contact, à distance, avec les professionnels de santé qui les suivent, afin d’améliorer l’équilibre de leur diabète.
L’application mobile DIABNEXT vient compléter le portefeuille produits de Glooko. Elle permet de suivre à distance les indicateurs essentiels à la prise en charge du diabète, facilitant la collaboration des médecins avec leurs patients afin de mieux prendre en charge la maladie. DIABNEXT dispose déjà d’une bonne implantation en France, et en rejoignant la famille Glooko, elle pourra accroître de façon significative le nombre de ses utilisateurs – patients et professionnels de santé sur le territoire national, tout en élargissant son offre de suivi à distance des patients.
« Nous sommes très heureux d’accueillir l’équipe de DIABNEXT au sein de Glooko. Ils disposent d’une expertise reconnue dans le secteur du diabète en France, et nous sommes particulièrement ravis d’intégrer leur produit déjà établi à notre offre », indique Russ Johannesson, PDG de Glooko. « En accueillant DIABNEXT, nous enrichissons notre offre d’une plateforme sans équivalent qui va nous aider à mieux personnaliser l’expérience patient et à améliorer la qualité de vie des personnes diabétiques. L’acquisition de DIABNEXT par Glooko confirme notre engagement à accroître notre présence mondiale et à proposer des solutions innovantes en permanence. »
L’équipe de DIABNEXT rejoint l’équipe Glooko au sein du bureau parisien de la société et propose désormais les deux plateformes sur le marché français. Glooko ambitionne de développer la communauté des patients diabétiques ou souffrant d’autres maladies chroniques, utilisateurs de ses plateformes. Laurent Nicolas, précédemment DG de DIABNEXT, pilote désormais les activités en France au poste de directeur général.
« Nous sommes ravis de rejoindre Glooko, une société dont nous apprécions les valeurs et qui permettra de développer des produits répondant spécifiquement aux besoins du marché français », souligne Laurent Nicolas. « Nous pourrons non seulement continuer à servir la communauté des patients diabétiques, mais nous pourrons également, en nous appuyant sur les ressources et les capacités d’intégration de Glooko, offrir plus d’outils pour aider les professionnels de santé à mieux accompagner leurs patients souffrant de maladies chroniques liées au diabète. »
Les patients, hôpitaux et cliniques qui utilisent actuellement le produit DIABNEXT continueront d’être pris en charge sur la plateforme. Glooko travaille actuellement sur le passage dans le droit commun du programme ETAPES (Expérimentations de télémédecine pour l’amélioration des parcours en santé) du Ministère des Solidarités et de la Santé. Ce programme vise à encourager et à soutenir le déploiement de projets de télésurveillance sur l’ensemble du territoire.
Il s’agit d’une bonne nouvelle pour les professionnels de santé français qui connaissent DIABNEXT et dont ils apprécient sa compréhension fine des besoins des médecins et des patients. « DIABNEXT apporte une contribution unique et essentielle à la prise en charge du diabète », déclare le Professeur Charles Thivolet, diabétologue, directeur et co-fondateur du centre DIABe-CARE. « Avec sa solution de télésurveillance déjà en place aux Hospices Civils de Lyon, DIABNEXT nous permet d’améliorer le parcours de soins et de personnaliser le suivi des patients. Avec DIABe-CARE, DIABNEXT est à la pointe de la télésurveillance des patients en France, et vient soutenir l’ambition française de fournir des technologies innovantes au secteur de la santé. »
La plateforme DIABNEXT sera commercialisée sous le nom de Glooko XT™.
A propos de Glooko
Glooko transforme la santé numérique en mettant en contact les personnes atteintes de diabète et d’autres maladies chroniques avec leurs équipes de soins de santé, ce qui favorise la télésanté collaborative, la recherche clinique et l’amélioration des résultats en matière de santé. Les plateformes logicielles de l’entreprise collectent et analysent les données de plusieurs appareils dans un seul endroit hautement sécurisé, ce qui permet un téléchargement à distance facile via une application ou en clinique, et produit des analyses faciles à lire grâce à des tableaux et des graphiques exploitables. La plateforme est compatible avec plus de 95 % des dispositifs mondiaux de surveillance du diabète et de la santé, ce qui donne aux patients et à leurs fournisseurs une flexibilité dans la prise en charge de leurs maladies. Avec plus de 35 milliards de données, Glooko est le leader mondial des données sur les patients diabétiques. Plus de 3 millions d’utilisateurs bénéficient déjà des solutions de Glooko dans 31 pays en 22 langues. Pour en savoir plus, consultez le site www.glooko.com
A propos de DIABNEXT
DIABNEXT a été fondée en vue de développer des solutions très innovantes qui aident les personnes diabétiques à mieux gérer leur maladie et à améliorer leurs soins et leur qualité de vie. Grâce à des collaborations avec de nombreux leaders d’opinion et cliniciens spécialisés en diabète, la plateforme DIABNEXT offre aux patients une solution unique automatisée qui permet la télémédecine, la coordination des équipes soignantes, l’éducation thérapeutique et le suivi à distance des données liées à la glycémie, à l’insuline, à l’alimentation et à l’activité physique, en se connectant à des dispositifs de santé.
Média, Amérique du Nord
Tanya Rodante
Directrice de la communication, Glooko
[email protected]
Média, Europe
Isabelle Guéguen
Responsable marketing, Glooko
[email protected]
+33 7 60 31 46 76
Combined Offering Provides all the Components of an End-to-End Platform
PALO ALTO, California, March 3, 2022 /PRNewswire/ – Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions, today announced a collaboration with Johns Hopkins HealthCare Solutions. Glooko’s cloud-based, device-agnostic platform and patient app will provide vitals capture and tracking enablement to the Johns Hopkins Blossom™ program, an interactive management program for people with diabetes, offered through employers, health plans and health care providers.
The Blossom solution provides an interactive experience that combines biometric data tracking, personalized skill-building content, and support from coaches to help people with diabetes better assess, understand, and optimize their care and build a healthier lifestyle. Blossom was developed to make diabetes management easier through lifestyle modifications while significantly improving health outcomes and reducing the cost of care.
“Glooko is pleased to work with Johns Hopkins HealthCare Solutions to enable a solution that helps patients, employees and health plan members succeed in making positive lifestyle adjustments and improve connections with their care teams, leading to better health,” said Glooko CEO Russ Johannesson. “Opportunities like the Blossom collaboration further expand Glooko’s value and offerings for our health care provider, payer and employer customers. We look forward to continuing to create real and meaningful differences in the lives of people with chronic conditions like diabetes, while reducing the cost of their care.” Published research has shown that remote patient monitoring coupled with clinically proven behavior change protocols can improve health outcomes among people with diabetes and reduces costs*.
Glooko’s cloud-based digital health platform and patient app integrate seamlessly into the Blossom solution, meeting patients where they are on their journey to better health. Glooko’s data tracking and sharing allows Blossom coaches and customer care teams to provide continuity of care in between doctors’ appointments–through personalized diabetes education content, care coordination and a 365-day coaching program–by identifying and closing any gaps in patient care. The ability to remotely share data also makes it possible to equip care teams with continual data to identify at-risk patients, intervene as needed, and provide more personalized, informed care.
The solution is available to payers, providers and self-insured employers immediately.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and other chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improved health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure place, allowing for easy remote upload via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in how to manage their conditions. With over 35B+ data points, Glooko is the global leader in diabetes patient data. More than 3 million users have already benefited from Glooko’s solutions in 29 countries across 22 languages. Learn more at glooko.com.
* Sources:
1. Tong Sheng, Linda Parks, Sarine Babikian, Vikram Singh, Mark A. Clements. Immediate and Sustained Trends in Glycemic Control during Remote Patient Monitoring in People with Type 2 Diabetes. ADA Scientific Sessions. June 2021
2. Tong Sheng, Linda Parks, Sarine Babikian, Vikram Singh, Michael Greenfield, Mark A. Clements Glycemic Improvements Following Mobile-Enabled Remote Patient Monitoring: A Randomized Control Study. ADA Scientific Sessions. June 2020.
3. Mark A Clements, Janelle Duffee, Dawn McCarther. Remote patient monitoring for adults with type 2 diabetes. ADCES Research Sessions. August 2020.
4. Maureen J. Lage & Kristina S. Boye (2020) The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database, Current Medical Research and Opinion, 36:9, 1441-1447, DOI: 10.1080/03007995.2020.1787971
###
Media Inquiries
Tanya Rodante
Director of Global Communication, Glooko
[email protected]
– Transaktion erweitert Glookos Expertise um Machine Learning und Just-In-Time Adaptive Intervention (JITAI) Technologien
– Digitale Interventionssysteme für chronische Erkrankungen
BERLIN, Deutschland, und PALO ALTO, USA. 31. Januar 2022 /PRNewswire/ – Glooko, Inc., ein führender Anbieter von Datenmanagement- und Telemonitoringlösungen für Diabetes und andere chronische Erkrankungen, gab heute die Akquisition des Berliner Digital Health Unternehmens xbird bekannt. xbird entwickelt Technologien, die Patienten und Gesundheitsversorgern die Vorhersage von Verhaltensmustern ermöglichen. Durch xbirds führende Just-In-Time Adaptive Intervention (JITAI) Technologie kann die Diabetestherapie individuell personalisiert werden.
xbirds Technologie wertet medizinische Daten und Verhaltensmuster gezielt aus, um daraus mithilfe neuester Erkenntnisse aus künstlicher Intelligenz (KI) und maschinellem Lernen (ML) Gesundheitsrisiken von Diabetespatienten zu identifizieren und maßgeschneiderte Vorschläge für die Therapie und den Lebensstil des einzelnen Patienten zu machen. Sensoren von Smartphones und Wearables zeichnen die Bewegungen von Patienten auf; die Daten werden analysiert, um individuelle Verhaltensmuster und personalisierte Vorschläge zur Verbesserung des Lebensstils und der Therapie von Patienten zu erstellen. Die Übernahme von xbird ergänzt die analytischen Kapazitäten und Technologien von Glooko und ermöglicht somit eine Weiterentwicklung von Glookos Plattform.
“Wir freuen uns sehr, das Team von xbird in der Glooko-Familie willkommen zu heißen. Unsere Investition in xbird steht für unser strategisches Interesse an maschinellem Lernen und personalisiertem digitalen Coaching von chronisch kranken Patienten”, sagte Russ Johannesson, Geschäftsführer von Glooko. “Unter den vielen JITAI Firmen im Digital Health Sektor verfügt xbird ganz klar schon heute über eine überlegene Lösung und hat erfolgreiche Partnerschaften mit Herstellern von Diabetesgeräten und klinischen Einrichtungen abgeschlossen. Die Kombination von Glookos globaler Präsenz und xbirds wegweisender JITAI Expertise wird es uns ermöglichen, die medizinische Versorgung von Patienten weiter zu verbessern.”
Sebastian Sujka, Gründer und Geschäftsführer von xbird, ergänzt: “xbird und Glooko passen großartig zusammen. Wir teilen unser Engagement für intelligente digitale Lösungen, die die Therapie von chronischen Erkrankungen verbessern und messbare Resultate liefern. Außerdem sind wir entschlossen, allen Patienten breitgefächerte medizinische Unterstützung zu bieten. Unser Ziel ist die Weiterentwicklung digitaler Gesundheitslösungen für möglichst viele Menschen mit chronischen Erkrankungen.” Die Glooko GmbH übernimmt alle Mitarbeiter von xbird und wird von Sebastian Sujka als Geschäftsführer geleitet.
Glooko wird die digitale JITAI Coaching Software von xbird in seine bestehende Plattform integrieren, die täglich von 7.500 Gesundheitseinrichtungen und mehr als 1,5 Millionen Patienten weltweit genutzt wird. Glooko plant, die neue Lösung allen Nutzer seiner Plattform weltweit zugänglich zu machen, damit sie mit ihrem Diabetes und damit zusammenhängenden chronischen Erkankungen besser leben können.
###
Über chronische Erkrankungen*
Weltweit leiden ungefähr 537 Millionen Erwachsene an Diabetes, darunter alleine 9,5 Millionen in Deutschland, d.h. 15,3% der Bevölkerung – Tendenz steigend. Deutschland befindet sich weltweit unter den Top 10 Ländern mit dem stärksten Anstieg an Diabetes. Darüber hinaus leidet fast die Hälfte aller über 15jährigen Deutschen an zwei oder mehreren chronischen Erkrankungen (verglichen mit einem Drittel der Weltbevölkerung). Nach Angaben des European Observatory on Health Systems and Policies ist einer von sechs Erwachsenen in Deutschland übergewichtig.
Über Glooko
Glooko verändert das digitale Gesundheitswesen, indem es Menschen mit Diabetes und verwandten Krankheiten und ihre medizinischen Betreuer miteinander vernetzt und so Telemedizin, klinische Forschung und bessere medizinische Ergebnisse ermöglicht. Die Software-Plattformen des Unternehmens unterstützen das Management von Diabetes und anderen chronischen Erkrankungen, indem sie die Daten von medizinischen Geräten und Apps nach höchsten Sicherheitsstandards verarbeiten. Die Daten werden per App oder in der Klinik hochgeladen und in aussagekräftigen Diagrammen und Grafiken visualisiert. Die Plattformen sind mit über 95% der weltweit erhältlichen Diabetes- und Gesundheitsüberwachungsgeräte kompatibel, so dass Menschen mit Diabetes und anderen chronischen Erkrankungen und ihre Pflegeteams die freie Wahl zwischen marktüblichen Geräten haben. Mehr als 3 Millionen Nutzer profitieren bereits von Glookos Lösungen zur Verarbeitung ihrer Gesundheitsdaten. Die Produkte werden von weltweit führenden Anbietern im Bereich Diabetes und chronische Erkrankungen genutzt und sind in 29 Ländern und 22 Sprachen verfügbar. Erfahren Sie mehr auf glooko.com.
Über xbird
xbird setzt Künstliche Intelligenz (KI) in der Medizin ein, um Lösungen zur Vorhersage von Gesundheitsrisiken und der Unterstützung von Diabetesmanagement zu entwickeln. Das Unternehmen sammelt Daten mithilfe von eingebauten Sensoren an Smartphones, Wearables, und medizinischen Geräten und entwickelt Algorithmen und Modelle von maschinellem Lernen, die auf Grundlage dieser Daten digitale Interventionssysteme (JITAI) ermöglichen. Seit seiner Gründung im Jahr 2015 durch Sebastian Sujka und Matteo Carli arbeitet xbird mit großen Pharma- und Medizintechnikunternehmen in Europa und den USA zusammen, um basierend auf KI individuelle Lösungen für Patientenverhalten und Therapieunterstützung anzubieten.
* Quellen:
1. International Diabetes Foundation
2. https://www.oecd-ilibrary.org//sites/5101558b-en/index.html?itemId=/content/component/5101558b-en#
3. OECD/European Observatory on Health Systems and Policies (2019), Germany: Country Health Profile 2019, State of Health in the EU, OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels.
###
Medienanfragen
Tanya Rodante
Director of Communication, Glooko
[email protected]
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
T: +49 40 88 16 59 64 /
T: +49 30 23 63 27 68
Acquisition expands Glooko’s digital health capabilities with machine learning
BERLIN and PALO ALTO, California, January 31, 2022 /PRNewswire/ – Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions today announced it has acquired xbird, a Berlin-based health AI company developing JITAI (Just In Time Adaptive Intervention) technologies to support patients and their providers in predicting behavior and managing diabetes.
Using the latest AI and machine learning, xbird’s technology has the capability of identifying health risks for people with diabetes by interpreting medical and behavioral data in a targeted manner and providing customized recommendations and behavioral nudges. Sensors via smartphones and wearables record a user’s movements and analyze the data to create individualized behavioral profiles and personalized nudges to change patient behavior and lifestyle decisions. The addition of xbird expands Glooko’s advanced analytics capabilities and tools, further broadening Glooko’s platform offerings.
“We are thrilled to welcome the xbird team to the Glooko family. Our investment in xbird represents Glooko’s strategic commitment to machine learning and customized digital coaching for patients with chronic conditions,” said Russ Johannesson, Glooko’s Chief Executive Officer. “Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution, and has built successful partnerships throughout diabetes device manufacturers and clinical institutions. The combination of Glooko’s established global footprint and xbird’s exciting JITAI capabilities will allow us to improve patient outcomes.”
Sebastian Sujka, Chief Executive Officer and Co-Founder of xbird stated, “xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible.” Mr. Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.
Glooko will integrate the xbird JITAI digital coaching software with its established platform which is used daily by more than 7500 clinics globally and over 1M users. Glooko plans to enable users of their platform globally to utilize these solutions to better manage their diabetes and related chronic conditions.
The Prevalence of Chronic Disease*
Approximately 537 million adults are living with diabetes worldwide, with 9.5 million in Germany (15.3% of the population) and the numbers continue to rise. It is ranked in the top 10 global countries with the fastest growth in diabetes. Additionally, almost one in two people in Germany over 15 years report living with two or more chronic conditions (versus approximately one third of people worldwide). According to the European Observatory on Health Systems and Policies, one in six adults are considered to be obese in Germany.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and other chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improved health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure place, allowing for easy remote upload via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in how to manage their conditions. More than 3 million users have already benefited from Glooko’s solutions in 29 countries across 22 languages. Learn more at glooko.com.
About xbird
xbird is a medical AI company developing ways to predict health risks and support diabetes management. The company captures data streams from built-in sensors on smartphones, wearables, and medical devices to develop algorithms and machine learning models which process these streams into real-time just in time adaptive interventions (JITAI). Founded in 2015 by Sebastian Sujka and Matteo Carli, xbird has collaborated with major European and US pharma and medical device companies to customize patient interaction and engagement with artificial intelligence.
* Sources:
1. International Diabetes Foundation
2. https://www.oecd-ilibrary.org//sites/5101558b-en/index.html?itemId=/content/component/5101558b-en#
3. OECD/European Observatory on Health Systems and Policies (2019), Germany: Country Health Profile 2019, State of Health in the EU, OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels.
###
Media Inquiries
Tanya Rodante
Director of Communication, Glooko
[email protected]
Forschungsdaten belegen: Vernetzte Pens verbessern Einhaltung regelmäßiger Insulindosierungen deutlich; ermöglichen längere Aufrechterhaltung des empfohlenen Glukosebereichs
GOTHENBURG, Schweden, 9. November 2021 /PRNewswire/ — Glooko Inc., ein führender Anbieter von Fernüberwachungs- und Datenmanagementlösungen für Diabetes und andere chronische Erkrankungen, gab heute eine strategische Zusammenarbeit mit Novo Nordisk bei der Entwicklung von vernetzten Insulin-Pen-Lösungen bekannt, die Menschen mit Diabetes in Deutschland und anderen europäischen Märkten zugute kommen wird. Im Rahmen dieser Zusammenarbeit integrieren die Unternehmen zwei neue vernetzte, intelligente Insulinpens, den NovoPen® 6 und den NovoPen Echo® Plus, in die mobilen Apps und cloudbasierten Plattformen von Glooko.
Die Plattformen von Glooko sind mit mehr als 95 Prozent der weltweit angebotenen Diabetesgeräte kompatibel. Die Zusammenarbeit mit Novo Nordisk baut auf dem geräteübergreifenden Geschäftsmodell des Unternehmens zur Fernüberwachung von Patienten und zum Management von Daten auf. Damit werden die Möglichkeiten des Versorgungsmanagements für Menschen mit Diabetes und ihre Gesundheitsdienstleister erweitert und können individuell angepasst werden.
Die neuen intelligenten Stifte zeichnen automatisch Dosierungszeiten und -mengen auf, speichern diese Daten bis zu drei Monate und ermöglichen die Übertragung in die Glooko-Plattform. Anders als herkömmliche Insulinpens, bei denen der Benutzer alle Daten zu jeder Insulindosis manuell aufzeichnen muss, ermöglichen die neuen Smart Pens nicht nur die lückenlose digitale Aufzeichnung der Insulindosierungsdaten, sondern bieten auch die Möglichkeit, die aufgezeichneten Daten per Nahfeldkommunikation (NFC) zu übertragen.
Durch die Integration der Berichts- und Analysefunktionen der Glooko®-Plattform ermöglichen die neuen intelligenten Pens den Patienten die Erfassung sämtlicher Dosierungsdaten und helfen ihnen und ihren Betreuern, verpasste Insulindosen schnell zu erkennen. Die Glooko-Integration ermöglicht es den Patienten auch, grafisch aufbereitete Daten einzusehen, die ihnen helfen, Trends zu erkennen und ihren Behandlungsplan zu verbessern.
„Wir freuen uns sehr über die Zusammenarbeit mit Novo Nordisk zur Integration unserer Diabetes-Produkte”, sagte Russ Johannesson, CEO von Glooko. „Studien haben gezeigt, dass sich Behandlungsergebnisse verbessern lassen, wenn intelligente Insulingeräte mit digitalen Gesundheitslösungen synchronisiert werden. Wir freuen uns über den weiteren Ausbau unserer Zusammenarbeit mit Novo Nordisk und darauf, Menschen in Deutschland zukünftig weitere innovative Produkte für eine verbesserte Einhaltung von Behandlungsplänen anbieten zu können.”
Der NovoPen 6 wurde in einer kürzlich in 12 Diabeteskliniken in ganz Schweden durchgeführten ersten Ergebnisstudie zum Einsatz von Smart Pens in der klinischen Praxis an Patienten getestet. Die Studie zeigte, dass sich die Anzahl der vergessenen Insulindosen zu den Mahlzeiten um 43 Prozent reduzierte (P=0,002). Außerdem erhöhte sich die Dauer, in der die Glukosewerte im empfohlenen Bereich lagen, deutlich, und zwar von 41,4 auf 49,9 Prozent (P<0,001).[1]
Glooko ist der weltweit führende Anbieter von Diabetes-Patientendaten, die über 32 Milliarden Datenpunkte umfassen. Durch die Integration der vernetzten Insulinpens von Novo Nordisk erhält Glooko Zugang zu weiteren Daten für zusätzliche internationale Märkte. Dies wird Gesundheitsdienstleistern und klinischen Forschern auf der ganzen Welt nutzen, indem sie Zugang zu weiteren klinischen Daten erhalten und diese in Studien zur Verbesserung von Therapien für Patienten mit chronischen Erkrankungen verwenden können.
Informationen zu Glooko
Glooko verändert das digitale Gesundheitswesen, indem es Menschen mit Diabetes und verwandten Krankheiten mit ihren medizinischen Betreuern vernetzt und so Telemedizin, klinische Forschung und eine verbesserte Zusammenarbeit ermöglicht. Die Software-Plattformen des Unternehmens, Glooko® und diasend®, unterstützen das Management von Diabetes und anderen chronischen Erkrankungen, indem sie die Daten von Blutzuckermessgeräten, CGMs, Insulinpumpen, vernetzten Insulin-Pens, Blutdruckmanschetten, Ernährungs-Apps, vernetzten Waagen und Aktivitäts-Trackern sammeln und nutzbar machen – und die Erkenntnisse an einem Ort zusammenführen. Die Daten werden per App oder in der Klinik einfach hochgeladen, unter hohen Sicherheitsstandards übermittelt und in aussagekräftigen Diagrammen und Grafiken visualisiert. Dies ermöglicht eine effiziente Zusammenarbeit von Patienten, Pflegern und Medizinern sowie sichere Behandlungsentscheidungen. Die Plattformen sind mit über 95 % der weltweit erhältlichen Diabetes- und Gesundheitsüberwachungsgeräte kompatibel, so dass Menschen mit Diabetes und anderen chronischen Erkrankungen und ihre Pflegeteams die freie Wahl zwischen marktüblichen Geräten haben. Mehr als 3 Millionen Nutzer profitieren bereits von den Lösungen von Glooko zur Verarbeitung ihrer Gesundheitsdaten. Die Produkte werden von weltweit führenden Anbietern im Bereich Diabetes und chronische Erkrankungen genutzt und sind in 29 Ländern und 22 Sprachen verfügbar. Erfahren Sie mehr auf glooko.com.
Medienanfragen Nordamerika
Tanya Rodante
Direktorin für Kommunikation, Glooko
[email protected]
Medienanfragen Europa
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888
Medienanfragen Deutschland
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
T: +49 40 88 16 59 64 /
T: +49 30 23 63 27 68
[1] Adolfsson P, Hartvig NV, Kaas A, Moller JB, Hellman J: Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. Diabetes Technology & Therapeutics 2020;22:709-718.
Research Finds Connected Pens Significantly Reduce Missed Doses and Improves Time in Recommended Glucose Range
Gothenburg, Sweden (PR NEWSWIRE) — November 9, 2021 – Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, announced a strategic collaboration with Novo Nordisk that will benefit people with diabetes in Germany, and other European markets, through the development of connected insulin pen solutions. Through this collaboration, the companies are integrating two new connected or “smart” insulin pens, NovoPen® 6 and NovoPen Echo® Plus, with Glooko’s mobile apps and cloud-based platforms.
Glooko’s platforms are compatible with more than 95 percent of diabetes devices globally. This collaboration with Novo Nordisk now expands upon the company’s device-agnostic model for remote patient monitoring and data management, expanding and customizing care management options for people with diabetes and their healthcare providers.
The new smart pens automatically record dosage times and amounts, storing up to three months of such data and enabling them to be transferred into the Glooko platform. Different from conventional insulin pens, which require the user to manually record all the data involved with each insulin dose, the new smart pens not only facilitate the uninterrupted digital recording of insulin dosing data, but also provide the possibility to transfer the recorded data via near-field communication NFC.
With the integration of the reporting and analytics functions of the Glooko® platform, the new smart pens enable patients to capture all their dosing data and help them and their providers quickly recognize data about missed insulin doses. The Glooko integration also makes it possible for patients to view data via graphically-oriented reports that can help them recognize trends so they can take action to improve their treatment plan.
“Glooko is very pleased to partner with Novo Nordisk on this integration of our products,” said Russ Johannesson, CEO of Glooko. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes. We are excited about the continued expansion of our working relationship with Novo Nordisk and look forward to providing more innovative products in the very near future for people in Germany looking to improve their health care regimens.”
NovoPen 6, in fact, was used by patients in the first real-world outcomes study using smart pens in clinical practice, which was conducted recently at 12 diabetes clinics across Sweden. The study showed that patients reduced the number of missed insulin bolus doses at mealtime by 43 percent (P=0.002). They also significantly increased the proportion of time their glucose levels stayed in the recommended range from 41.4 to 49.9 percent of the time (P<0.001).
Glooko is the global leader in diabetes patient data with over 32 billion data points. Adding Novo Nordisk’s connected insulin pens in additional global markets will increase this data at Glooko, and benefit healthcare providers and clinical researchers around the world, via access to real world data and applying it to studies for improved therapeutics for patients with chronic conditions.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and related conditions and their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms, Glooko® and diasend®, empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with over 95% of global diabetes devices along with health monitoring devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 29 countries across 22 languages. Learn more at glooko.com.
# # #
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]
Media, Europe
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888
Prakash Menon brings extensive AI and enterprise software expertise to the global leader in connected chronic care management
Palo Alto, CA, August 9, 2021 /PR NEWSWIRE/ — Glooko Inc., the leading provider of remote patient monitoring and data management platforms in diabetes and related chronic conditions, today announced the appointment of Prakash Menon as the Company’s Chief Technology Officer.
As a proven technology executive with more than 30 years of experience in enterprise software development, Menon will bring deep enterprise software expertise to Glooko’s goal of building the most innovative digital platforms that connect people with chronic conditions and their care providers, for better health outcomes.
Menon has an extensive track record in SaaS, enterprise software development, AI, technical leadership, and entrepreneurial experience. In addition to enterprise application development, his areas of expertise include distributed systems integration, database (SQL and NoSql) in and out of the cloud and building and deploying machine learning (ML) models to production scale. He has built and led teams that deliver solutions that require ML, business analytics, application development, mobile development and open API development.
Most recently he served as Chief Technology Officer of Genalyte and delivered a multi-antigen analysis algorithm for a COVID-19 antibody test using ML in three weeks, leading to an investment by Verily (Google Health).
Prior to this, Menon spent 7 years in the roles of CTO, Interim CEO and Board Member at BaseHealth. During his time at BaseHealth his team built and delivered five novel AI products that use ML and deep learning to accurately predict the onset of the world’s most devastating diseases. His team architected an ML platform that processed 350 million data points over 263,000 lives across hybrid cloud technologies.
Menon’s unique software perspective and his extensive background in creating and scaling large-scale cloud software systems will serve Glooko’s global patient base, healthcare providers and technology partners, at a time when the industry is tackling the challenges of standardization and scale within digital healthcare. Glooko currently provides remote patient management and connected care platforms in diabetes and related chronic conditions such as obesity and hypertension. With recent funding, the Company is expanding into additional indications and global markets.
“I’m excited to join Glooko and help the team scale to deliver superior platforms for connecting patients with their healthcare providers for better care,” Menon said. “I’m impressed with Glooko’s proven technology that has shown to improve outcomes for people with chronic diseases, and I’m ready to help make that happen at a whole new level.”
Russ Johannesson, Chief Executive Officer at Glooko stated, “We are so pleased to welcome Prakash to our Executive Leadership Team. He brings an impressive track record of leading successful teams in building healthcare enterprise systems and scaling those systems for rapid growth. Even in a place such as Silicon Valley, his credentials stand out. We are excited to see him take Glooko’s products to next-level.”
Johannesson continued, “Additionally, we are very proud of the contributions that Kyle Brown, our outgoing CTO has made at Glooko. His impact in his time here has been very positive to building Glooko’s platforms to where they are today for our worldwide patients and healthcare providers. We wish him all the best and a very happy retirement.”
About Glooko
Glooko is transforming digital health by connecting people with diabetes and related conditions and their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected weight scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with over 95% of global diabetes devices along with health monitoring devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 28 countries across 21 languages. Learn more at glooko.com.
Media Contacts:
Tanya Rodante
Director of Global Communication, Glooko
[email protected]
Presented at 2021 Annual Meeting of the American Diabetes Association
WASHINGTON, June 25, 2021 /PRNewswire/ — A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D). Participants remotely shared their glucose data with care teams and received remote-based coaching interventions. The data will be presented during a poster session beginning today at the 81st Scientific Sessions (virtual) of the American Diabetes Association and are sponsored by Glooko, Inc.
The study investigated whether PWT2D demonstrated improved glycemia after participating in RPM programs of varied scope and duration at 11 different healthcare systems across the United States. Program participants were instructed to regularly sync their blood glucose meters with either a mobile app or a computer-based software during the program. Synced glucose data were made available to the RPM care teams via a web-based dashboard, and remote coaching was administered either regularly and/or as needed. The study’s analyses evaluated glycemic outcomes derived from self-monitoring of blood glucose (SMBG) data recorded from RPM program participants at various intervals throughout the RPM program (up to 12 months).
The results show immediate (3 months) and sustained (6 and 12 months) glycemic improvement compared to baseline (all Ps < .05), including:
1. Decrease in average glucose by ~12% (~20 mg/dL)
2. Increase in the average proportion of in-range (70-180 mg/dL) glucose readings by ~22% (~13 percentage points)
3. Decrease by ~42% (~6 percentage points) in the average proportion of high glucose readings (>250 mg/dL)
The analysis included 424 PWT2D among whom 46% were females and the median age [IQR] was 50 [42-59] years. Cross-sectional comparisons were made at the start of the program and at 3 (N3 = 331), 6 (N6 = 228), and 12 months (N12 = 129) of RPM program participation.
“The emergence of digital health tools like connected devices and mobile apps for self-management has not only helped people with type 2 diabetes in the daily management of their disease but also facilitated the sharing of their data with their care teams,” said Mark Clements, MD, PhD, Chief Medical Officer of Glooko and practicing endocrinologist. “These results demonstrate that, with access to patient data, care teams can identify patients with sub-optimal glycemic control and provide them with timely, remote-based interventions outside of routine clinic visits that lead to significant glycemic improvements in the near term as well as on a sustainable basis.”
The analysis also found that the average proportion of hypoglycemic readings (<70 mg/dL) did not change.
The poster at the virtual ADA meeting is # 467-P, “Immediate and Sustained Trends in Glycemic Control during Remote Patient Monitoring in People with Type 2 Diabetes,” by Tong Sheng, PhD, Sarine Babikian, PhD, Vikram Singh, M Eng, and Mark A. Clements, MD, PhD.
Additionally at ADA, the Company will present the following on-demand panel:
Registered attendees of the 81st Scientific Sessions of the American Diabetes Association will have on-demand access online to “Between Two Appointments: How to Leverage Daily Diabetes Data (In-clinic & Remote) to Improve Patient Outcomes,” an expert-led ADA Diabetes Learning Byte panel. This 20-minute discussion will be with endocrinologist Mark Clements, MD, PhD, Chief Medical Officer, Glooko and Zach Henderson, Chief Commercial Officer, Glooko, both industry veterans with extensive background in healthcare data and analytics. They will explore how to leverage patient diabetes data captured by glucose meters, pumps, smart pens, fitness and health apps, and other wearables and use it in ways that lead to healthy patient outcomes. They will also discuss available solutions for remotely using patient-collected data between appointments to better inform care plans and address emerging risks. The on-demand presentation will be available June 25 through September 29 via the registration of ADA attendees at https://professional.diabetes.org/meetings/81st-registration-information.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and other chronic conditions with their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. The platforms are compatible with over 95% of global diabetes devices along with biometric devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 28 countries across 21 languages. Learn more at glooko.com.
Media Contact:
Tanya Rodante
Director of Global Communication, Glooko
[email protected]
Gothenburg, Sweden (PR NEWSWIRE) May 6, 2021 Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, today announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions. The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly’s Tempo Pen™ and Tempo Smart Button™ (currently in late-stage development) with Glooko’s platform.
Glooko’s platforms are compatible with over 95 percent of diabetes devices globally, and the Lilly collaboration expands upon the Company’s device-agnostic model for remote patient monitoring and patient data management. This gives patients and their healthcare providers more freedom of choice for managing their care.
The Tempo Pen is an enhanced version of Lilly’s current prefilled, disposable insulin pen to which the Tempo Smart Button (pending CE mark) attaches. Through this new agreement, the Tempo Smart Button will pair with Glooko’s software to facilitate the integration of personalized healthcare data from the Tempo Pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers and food logs. The integrated and actionable insights available in Glooko will improve the standard of diabetes care.
“Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch,” said Russ Johannesson, CEO of Glooko. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes. We are excited about continuing to expand the availability of our solution and look forward to helping more people manage their diabetes through our innovative products.”
Lilly aims to receive CE mark for the Tempo Smart Button later in 2021 and will launch the Tempo Pen and Tempo Smart Button with Glooko’s platform following this certification.
“We’re pleased to work alongside Glooko on our commitment to improving diabetes outcomes by bringing together medicine and digital solutions for the global diabetes community,” said Marie Schiller, Vice President of Product Development for Connected Care and Insulins at Lilly. “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses. By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.”
Glooko is the global leader in diabetes patient data with over 32 billion data points. Adding Lilly’s connected insulin pens in additional global markets will increase this data at Glooko, and benefit healthcare providers and clinical researchers around the world, via access to real world data and applying it to studies for improved therapeutics for patients with chronic conditions.
About Diabetes
An estimated 463 million adults worldwide(1) have diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.(2)
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.
About Glooko
glooko.com.
Contacts:
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]
Media Europe
Anders Sonesson
General manager EMEA/APAC, Glooko
[email protected]
+46735458888
_________
(1) International Diabetes Federation. IDF Diabetes Atlas, 9thedn. Brussels, Belgium: International Diabetes Federation, 2019. Available at:http://diabetesatlas.org.
(2) Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services; 2020.
New Capital Reflects the Company’s Increasing Trajectory and Market Growth
PALO ALTO, CA, March 16, 2021 /PRNewswire/- Glooko Inc., a leading provider of remote patient monitoring and chronic care management solutions including diabetes and obesity has raised a $30 million Series D round of funding. The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic. Proceeds will be used to accelerate organic growth and strategic initiatives across the company’s broad and growing product line of advanced digital health solutions.
“Glooko has done a remarkable job of bringing to market cutting edge digital healthcare platforms, which empower people with diabetes to better manage their disease and improve their lives. This technology enables physicians to take better care of patients with diabetes by strengthening the engagement between people with diabetes and their healthcare providers,” said Charles Boorady, Founder & Managing Partner of Health Catalyst Capital. “As a result of Glooko’s innovations, the company has experienced rapid market adoption growing its global ecosystem to more than 7,500 clinics and has entered into partnerships with many of the world’s largest diabetes medical device companies and pharmaceutical companies as well as top healthcare systems. We look forward to supporting the company in its next phase of growth as it invests in new capabilities supporting the management of chronic care and serving even more stakeholders.”
This round of financing follows a successful 2020 for Glooko, the most successful in its history despite the global pandemic. Last year, the Company’s growth included key partnerships with major healthcare systems and extended long-term existing partnerships with several global diabetes industry leading companies such as Insulet and Novo Nordisk.
The new proceeds will accelerate execution of Glooko’s commercial strategy, including increasing adoption of Glooko’s remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional therapy areas.
This is an unprecedented time in healthcare and technology. The demand for our platform demonstrates this sea-change. Glooko has experienced considerable growth, and this funding allows us to build on our strong momentum in providing the advanced technologies we’re known for,” said Russ Johannesson, CEO of Glooko. “Now more than ever, the healthcare industry is seeking new and smarter technologies, whether it’s for patient care or researching new therapies. I am excited to lead the team at Glooko in our mission to improve health outcomes by connecting people with diabetes and other chronic conditions with their healthcare professionals.”
About Glooko
Glooko is transforming digital health by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. Over 3 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 27 countries across 20 languages. Their US headquarters are located in Palo Alto, CA with European headquarters in Gothenburg, Sweden. Learn more at glooko.com
About Health Catalyst Capital
Health Catalyst Capital Management is an independent fund manager investing in private, growth-stage healthcare information technology and technology-enabled services businesses that seek to improve the human condition and promote value-based care.
HCC was formed by a team of experienced healthcare investors and operators seeking profitable investment opportunities, while at the same time seeking to improve the human condition and promote value-based care.Learn more at healthcatalystcapital.com
Investors
Steve Lien
Chief Financial Officer, Glooko
+1650-720-5310
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]
Media, Europe
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888